PARIS | November 13th, 2024 – Bryan Garnier is pleased to release “Long-Acting Injectables: A Lasting Dose of Innovation,” an in-depth exploration of how long-acting injectables (LAIs) are transforming patient care and driving expansion across diverse therapeutic areas.
While LAIs have proven essential in psychiatry, their impact now reaches into fields like opioid use disorder (OUD), and oncology, with obesity emerging as the next frontier. In Schizophrenia alone, the USD 4 billion LAI market continues to expand, with LAIs capturing over 15% of the antipsychotic segment alone, offering reduced dosing frequency and lowering relapse risks.
Beyond LAIs, reformulation innovations such as oral biologics, fast-acting injectables, and enhanced bioavailability technologies are accelerating interest among investors and healthcare providers, paving the way for new therapeutic possibilities.
In this report, we examine these transformative developments and profile key innovators advancing long-acting solutions.
To access these insights and explore the future of patient-centric therapies, download our full report here.
Oscar Haffen-Lamm
BG IRIS
About Bryan, Garnier & Co
Bryan, Garnier & Co is a European growth investment bank that helps healthcare and technology companies become global champions. By combining extensive sector expertise with an entrepreneurial mindset, Bryan Garnier provides companies and their investors with independent growth strategic advice, and privileged access to buyers and capital in Europe, the US and Asia.
As a full-service investment bank, the firm offering includes private and public growth financing solutions, mergers and acquisitions (M&A) advisory, research insights, and institutional sales & execution. Founded in 1996, Bryan Garnier & Co is an independent partnership with around 200 employees located in major financial centres in Europe and the US.